| Theme | Recent advance in the treatment of IBD based on the pathogenesis | |
|---|---|---|
| Title | IL-12/23 antagonist | |
| Publish Date | 2018/05 | |
| Author | Taku Kobayashi | Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital |
| [ Summary ] | Ustekinumab, an anti-IL-12/23 antibody, has recently become available in Japan. IL-12 and 23 are cytokines which are produced by innate immune cells and promote Th1/Th17 responses, located upstream of the pathogenesis of Crohn's disease (CD). The efficacy of ustekinumab has been confirmed by a phase 3 randomized controlled trial. It is expected to improve treatment outcomes CD by its inhibition of non-TNF pathways, provide excellent safety profiles and have low immunogenicity. | |